Second-generation inhibitors of fatty acid synthase for lung cancer treatment

被引：0
|
作者：
Orita, H.
Coulter, J.
Tully, E.
Pinn, M.
Thupari, J.
Pomper, M.
Townsend, C.
Ettinger, D.
Kuhajda, F.
Gabrielson, E.
机构：
[1] Juntendo, Tokyo, Japan
[2] Johns Hopkins Sch Med, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18185
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Treatment by second-generation tyrosine-kinase inhibitors in patients with imatinib failure
    Etienne, G.
    ONCOLOGIE, 2012, 14 (10-11) : 589 - 595
  • [22] Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
    Dow D.E.
    Bartlett J.A.
    Infectious Diseases and Therapy, 2014, 3 (2) : 83 - 102
  • [23] Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
    Dick, Lawrence R.
    Fleming, Paul E.
    DRUG DISCOVERY TODAY, 2010, 15 (5-6) : 243 - 249
  • [24] Cancer genetics - Second-generation models
    Packer, A
    NATURE REVIEWS GENETICS, 2004, 5 (12) : 888 - 888
  • [25] Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : S146 - S149
  • [26] Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Sequist, Lecia V.
    ONCOLOGIST, 2007, 12 (03): : 325 - 330
  • [27] Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer
    Abbasi, Ali
    Movahedpour, Ahmad
    Amiri, Ahmad
    Najaf, Mohamad Samare
    Mostafavi-Pour, Zohreh
    CURRENT MOLECULAR MEDICINE, 2021, 21 (04) : 332 - 346
  • [28] Re: Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
    van der Poel, Henk G.
    EUROPEAN UROLOGY, 2009, 56 (03) : 575 - 575
  • [29] BTK inhibitors in CLL: second-generation drugs and beyond
    Tam, Constantine
    Thompson, Philip A.
    BLOOD ADVANCES, 2024, 8 (09) : 2300 - 2309
  • [30] Impact of Second-Generation Tyrosine Kinase Inhibitors As Second Line Treatment for Patients with Chronic Myeloid Leukemia
    Valentin Garcia-Gutierrez, J.
    Herrera, Pilar
    Abalo, Lorena L.
    Dolores Rey, Maria
    Calbacho, Maria
    Ramos, Lourdes
    Ramos, Paloma
    Montalban, Carlos
    Lopez-Jimenez, Javier
    BLOOD, 2011, 118 (21) : 1615 - 1615
12345